Background: Early diagnosis of hepatitis C virus (HCV) infection is essential to allow appropriate treatment and prevent transmission. Objectives: To evaluate the Elecsys ® Anti-HCV II assay as a routine screening assay in Asia using a large number of samples from different Asian Pacific populations and compare its performance with other HCV assays routinely used in the region.
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® Anti-HCV II assay was more sensitive in recognizing early infection and detected acute HCV infection earlier on average than the comparator assays for all six panels tested. 7 ,726 routine samples were tested and 322 identified as HCV positive. Elecsys ® Anti-HCV II had a sensitivity of 100% and a specificity of 99.66%, both of which were comparable or superior to the results obtained for competitor assays, which ranged from 87.5-100% and 98.98-100%, respectively.
Conclusions: The Elecsys
® Anti-HCV II assay has the sensitivity and specificity to support its use as a routine screening method in the Asia Pacific region. Furthermore, this assay shortens the diagnostic window between infection and the detection of antibodies compared with established methods.
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Background
Hepatitis C virus (HCV) infection is a global health burden; approximately 170 million people are chronically infected worldwide and HCV-related liver disease is responsible for over 250,000 deaths annually [1, 2] . Over 50% of all HCV-positive individuals live in the Asia Pacific region where prevalence rates range from 1.0% in Singapore to 5.5% and 5.6% in Taiwan and Thailand, respectively, and 15.6% in Mongolia [3] [4] [5] [6] . An estimated 83 million people living in the Asia Pacific region and 400,000 in Australia and Oceania are chronically infected with HCV [3] .
As there is currently no vaccine against the infection, prevention of transmission relies on the diagnosis, appropriate education and treatment of infected individuals. However, many patients remain undiagnosed [7] , partly due to the asymptomatic nature of most chronic infections. Once the infection has been diagnosed it can be successfully treated in most cases with peginterferon and ribavirin [5, 8] . There have also been several advancements in HCV therapy over recent years, with the licensing of boceprevir and telaprevir in 2011, and more recently of simeprevir and sofosbuvir [9] [10] [11] [12] .
In many clinical laboratories anti-HCV assays remain the first choice for testing samples for HCV infection. Anti-HCV assays have evolved and those currently available detect infection earlier and have improved sensitivity and specificity compared with older generation assays [2, 13] . The Elecsys ® Anti-HCV II assay (Roche Diagnostics GmbH, Penzberg, Germany) was developed to offer enhanced seroconversion sensitivity, specificity and convenience over the Elecsys ® Anti-HCV assay. It is a qualitative electro-chemiluminescence immunoassay and uses recombinant antigens and synthetic peptides, labeled core, NS3 and NS4 antigens to detect HCV antibodies in the sample [14, 15] . The performance of the Elecsys ® Anti-HCV II assay was established by a CE evaluation study comparing the two Elecsys ® assays with other commercially available anti-HCV assays in routine clinical use and as a result it is CE approved for diagnostic use and for screening blood donations [14] .
Objectives
To evaluate the Elecsys ® Anti-HCV II assay as a routine screening assay in Asia using a large number of samples from different Asian Pacific populations. We also aimed to compare its performance with that of other HCV assays routinely used in the region and to verify the initial sensitivity and specificity findings for the assay.
Study Design

Centers and assays compared
The study was performed at nine independent centers as shown in Table 1 . Each tested the Elecsys ® Anti-HCV II assay [15] and at least one comparator assay: ARCHITECT TM Anti-HCV (Abbott Laboratories, Wiesbaden, Germany) [16] ; Serodia ® -HCV Particle Agglutination (Fujirebio, Tokyo, Japan) [17] ; Vitros ® ECi Anti-HCV (Ortho Clinical Diagnostics, High Wycombe, UK) [18] ; Elecsys ® Anti-HCV (Roche Diagnostics, Penzberg, Germany) [19] ; ADVIA Centaur ® HCV (Siemens Healthcare Diagnostics, Marburg, Germany) [20] ; InTec ® HCV EIA (InTec Products Inc., Xiamen, China) [21] ; Livzon ® Anti-HCV (Zhuhai Livzon Diagnostics Inc., Zhuhai, China) [22] . All assays were used according to the manufacturers' instructions [15] [16] [17] [18] [19] [20] [21] [22] .
Samples
Details of the samples tested by each center are shown in Table 1 . These included several commercially available seroconversion panels as follows: PHV912, PHV919, PHV921 (SeraCare Life Sciences Inc., Milford, USA); HCV6212, HCV6224, and HCV 9058 (ZeptoMetrix Corporation, Buffalo, USA) (all composed of sera collected from the USA).
Serum samples provided by each center (Table 1) were tested with the Elecsys ® Anti-HCV II assay and other center specific comparator assays to determine assay sensitivity and specificity. These samples were received by the respective laboratory with a request for HCV testing and were routine hospital samples sent for screening. The samples included those from patients on dialysis and with thalassemia, as well as those positive for potentially cross-reacting factors such as hepatitis B virus, hepatitis A/E virus, rheumatoid factor, human immunodeficiency virus (HIV), systemic lupus erythematosus and autoimmune hepatitis (Table 1 ).
Methods and analyses
Results for the Elecsys ® Anti-HCV II assay were expressed as a signal to cut-off (s/co) ratio; a s/co ratio<0.9 indicated a negative result while a s/co ratio ≥1.0 was positive. A s/co ratio between 0.9 and <1.0 was considered to fall into a gray zone and these samples were considered positive for calculations within this study [15] . Results obtained from the comparator assays were interpreted according to the information provided by the manufacturer; results that fell into the gray zone given for comparator assays were also considered to be positive [16] [17] [18] [19] [20] [21] [22] . If the results using two or more assays to test the same sample were concordant and the s/co ratio for both assays was ≥5 the sample was deemed to be positive and verification was not required. Discrepant samples and samples with concordant positive results but a s/co ratio <5 were subject to additional confirmatory testing using a third immunoassay and/or an HCV immunoblot. The verification methods are shown in Table 1 .
Seroconversion panels were used to assess how early each assay could detect infection. Comparisons of seroconversion sensitivity were made by calculating the time at which the anti-HCV assays detected the sample as being positive compared with the HCV RNA test result; the positive nucleic acid test result was considered as day 0.
The assay sensitivity and specificity were determined using the daily routine samples. All HCV immunoblot-positive samples were deemed to represent positive samples and were included in the sensitivity calculations. Similarly, HCV immunoblot-negative samples were considered negative and included in the specificity calculation while HCV immunoblot-indeterminate samples were excluded.
Results
Early detection sensitivity
The Elecsys ® Anti-HCV II assay was more sensitive in recognizing early HCV infection than the comparator assays (Table 2 and Fig. 1 ). The assay detected acute HCV infection earlier on average than the comparator assays, including the ARCHITECT TM Anti-HCV assay, for the panels tested.
Positivity of HCV infection and assay sensitivity
Of the 7,726 routine samples tested, 322 were identified as positive resulting in an overall positivity of HCV infection of 4.2%. The positivity determined at the individual centers is shown in Table 1 . The Elecsys ® Anti-HCV II (n = 322), Elecsys ® Anti-HCV (n = 38), Vitros ® ECi Anti-HCV (n = 54), and ADVIA Centaur ® HCV (n = 19) assays all had a sensitivity of 100%. However, false-negative results were observed with the ARCHITECT TM Anti-HCV (sensitivity 251/258 [97.3%]), InTec ® HCV EIA (sensitivity 7/8 [87.5%]), and Livzon ® Anti-HCV (sensitivity 7/8 [87.5%]) assays. Statistical significance cannot be demonstrated for these results due to the different number of samples tested with each assay. Twenty-nine samples were excluded from the sensitivity calculations due to indeterminate HCV immunoblot results.
Specificity
The overall specificity of the Elecsys ® Anti-HCV II assay using the routine samples was 99.66% and was comparable to, or better than, the specificity of the other assays tested. Using a lower total number of samples, the overall specificity of the comparator assays varied from 98.98% (Elecsys ® Anti-HCV; n = 1,616) to 100% (InTec ® HCV EIA; n = 1,044). These data are shown in Table 3 along with the specificity data from the individual centers. The Table 2 Seroconversion sensitivity of the assays tested. Serodia ® -HCV Particle Agglutination assay was not used to test routine samples. The specificity of the Elecsys ® Anti-HCV II assay was not affected by potentially cross-reacting factors and was found to be 100% (98.28-100%) in samples from 214 patients with thalassemia or undergoing dialysis compared with 96.23% (92.70-98.36%) for the Vitros ® ECi Anti-HCV assay (eight false-positive results). Similarly, the specificity of the Elecsys ® Anti-HCV II assay was determined to be 99.50% (98.22-99.94%) in 443 patients with other potentially cross-reacting factors compared with 99.50% (98.22-99.94%) for the Elecsys ® Anti-HCV assay, 99.75% (98.63-99.99%) for the InTec ® HCV EIA and 100% (99.09-100%) for the Livzon ® Anti-HCV assay.
Discussion
This study demonstrates that the Elecsys ® Anti-HCV II assay has the sensitivity (100%) and specificity (99.66%) in samples from Asian Pacific populations to support its use as a routine screening method in the region. Furthermore, the seroconversion panel results show that the Elecsys ® Anti-HCV II assay detects infection sooner than the comparator assays.
In the multicenter CE study, the Elecsys ® Anti-HCV II assay detected infection on average 3.8 days sooner than the previous version of the test (Elecsys ® Anti-HCV) [14] . The results obtained here demonstrate a greater potential sensitivity as the Elecsys ® Anti-HCV II assay detected seroconversion a mean of 6 days before the Elecsys ® Anti-HCV assay and soon after the HCV RNA test. Hence, the assay technology (double-antigen sandwich), use of polypeptides and recombinant antigens, and unique antigen combination appear to enhance the sensitivity for early detection of infection as discussed previously [23] . Of note, the InTec ® HCV EIA and Livzon ® Anti-HCV assays, which are not generally considered to be state-of-the-art assays, were the least sensitive for early detection and did not detect infection until more than 12 days on average after the ARCHITECT TM Anti-HCV assay.
The prevalence of HCV in the Asian Pacific region varies widely [3] [4] [5] [6] and is reflected by the HCV positivity found at the participating sites, which ranged from 0.2% to 8.6%. However, as the samples tested in this study were not randomly selected (but sent with a specific request for HCV testing) the results cannot be used to generate prevalence estimates.
The sensitivity of the Elecsys ® Anti-HCV II assay in samples from Asian Pacific populations was found to be 100%. This value compares favorably with previously reported sensitivities for the assay (also 100% [14, 15, 23, 24] ) and is similar or superior to that of the other assays tested within this and other studies: ARCHITECT TM Anti-HCV, 94.44-100% [14, 23, 25, 26] ; Elecsys ® Anti-HCV, 100% [14, [24] [25] [26] ; Vitros ® ECi Anti-HCV, 99.5%-100% [23, 24, 26, 27] ; and ADVIA Centaur ® HCV, 97.5-100% [14, 25, 28] . The InTec ® HCV EIA and Livzon ® Anti-HCV assays were the least sensitive (87.5% for each). It is important to note that some of the studies mentioned above were conducted using samples from European populations [14, 25, 28] and several used fresh sera from blood donors as well routine unselected clinical samples or preselected sera with low positive anti-HCV results [14, 23, 25] .
Given the high variability of HCV it is important that diagnostic assays detect infection regardless of the genotype and subtype. Several of the previous studies have investigated the sensitivity of the assay for detecting individual HCV genotypes by genotyping samples from patients known to be HCV positive prior to testing [14, 23] . For example, Esteban and colleagues specifically looked at genotypes 1-6 [14] and Yang and colleagues investigated 203 samples with confirmed genotypes 1b, 2a, 3a, 3b and 6a, which are endemic to China [23] . Although in this study samples positive for known genotypes were not tested, a large number of routine clinical samples were assessed. These are likely to represent the genotypes and subtypes most prevalent in the region (such as genotypes 1b, 3 and 6a) [29] and all of these samples were correctly identified as positive by the Elecsys ® Anti-HCV II assay. Furthermore, we found the specificity of the Elecsys ® Anti-HCV II assay to be similar or superior to that of the other assays tested. Combining our findings with those previously published, the specificity is 99.64-99.66% for the Elecsys ® Anti-HCV II [14, 23] , 98.8-99.76% for the ARCHITECT TM Anti-HCV [14, 23, 25, 26] , 99.1-99.9% for the Elecsys ® Anti-HCV [14, 24, 25] , 96.5-99.76% for the Vitros ® ECi Anti-HCV [23] [24] [25] [26] [27] 30] and 99.05-99.9% for the ADVIA Centaur ® HCV assay [25, 28] . In addition, our results confirm those of the multicenter CE study and demonstrate that the assay is suitable for use in a variety of populations [14] .
According to the Asian Pacific Association for the Study of the Liver guidelines, samples that are anti-HCV positive should ideally be retested using a second assay with high specificity. However, this increases the cost of testing and hence may not be possible. As an alternative, the guidelines state that: 'Samples reactive in an approved single EIA can be reported as anti-HCV positive provided the signal to cut-off ratio is sufficiently high to be predictive of a true positive' [8] . In this study samples did not need to be verified if the results using two or more assays to test the same samples were concordant and the s/co ratio for both assays was ≥5; this was to avoid extensive and expensive confirmation by alternative techniques. In total 307 samples did not require verification. While a threshold has not been established for this new version of the assay, a study of the Elecsys ® Anti-HCV assay suggested a s/co ratio ≥150 was highly predictive (≥95%) of infection status, as determined by supplemental recombinant immunoblot assay testing, and could avoid 90% of supplementary testing [31] . Analysis of previous results using the Elecsys ® Anti-HCV II assay suggest that a s/co ratio of 20.0 is predictive of a true positive result ≥95% of the time [23] . However, further investigations are required before this value can be adopted [23] . Interestingly, Wu et al. investigated the appropriate s/co thresholds for several assays currently used in China and determined them to be 12.0 for the InTec ® assay and 5.0 for the ARCHITECT TM assay [32] . These results confirm earlier findings suggesting a s/co ratio of ≥8.6 for the InTec ® assay predicted 96.1% of true positive results [33] .
In conclusion, this study confirms the very good specificity and superior sensitivity of the Elecsys ® Anti-HCV II assay and shows that it shortens the diagnostic window between infection and the detection of antibodies, compared with established routine methods. 
